TIDMFARN

RNS Number : 4134T

Faron Pharmaceuticals Oy

25 March 2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Exercise of options

Issue of equity

Company announcement, 25 March 2020 at 9.45 AM (EET)

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that it has received a notification from Toni Hänninen, Faron's CFO, to exercise D options over 40,000 ordinary shares in the Company at an exercise price of EUR 1.09 (approx. GBP 0.94) per share under the Company's 2015 Option Plan ("New Ordinary Shares"). The terms and conditions of the 2015 Option Plan are available on the Company's website at https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%20Conditions_20200518.pdf .

Applications will be made to the London Stock Exchange and Nasdaq Helsinki to admit the New Ordinary Shares to trading on AIM and Nasdaq First North Growth Market, respectively. Admission of the New Ordinary Shares is expected to occur on or around 7 April 2021 following issue and registration of the New Ordinary Shares on or around 6 April 2021 ("Registration"). The New Ordinary Shares will rank pari passu with existing ordinary shares.

Faron's enlarged issued number of shares immediately following Registration will be 50,457,874 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, Registration, the total number of voting rights in Faron will be 50,457,874. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner, Mark Rogers

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Broker

Rupert Dearden

Phone: +44 207 886 2500

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

Email: faron@consilium-comms.com

Stern Investor Relations

Julie Seidel, Naina Zaman

Phone: +1 (212) 362-1200

Email: faron@sternir.com

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine(R) is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine(R) is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------------------------------------ 
 a.    Name                       Toni Hänninen 
                                 --------------------------------------------------------- 
 2     Reason for notification 
      -------------------------  --------------------------------------------------------- 
 a.    Position/Status            Person discharging managerial responsibilities 
      -------------------------  --------------------------------------------------------- 
 b.    Initial notification/      Initial notification 
        Amendment 
      -------------------------  --------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------ 
 a.    Name                       Faron Pharmaceuticals Oy 
      -------------------------  --------------------------------------------------------- 
 b.    LEI                        7437009H31TO1DC0EB42 
      -------------------------  --------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  ------------------------------------------------------------------------------------ 
 a.    Description of             Options over ordinary shares 
        the financial 
        instrument, type           ISIN: FI4000153309 
        of instrument 
 
        Identification 
        Code 
      -------------------------  --------------------------------------------------------- 
 b.    Nature of the              Exercise of options made pursuant to the Faron 
        transaction                Option Plan 2015 exercisable at EUR1.09 per 
                                   ordinary share 
      -------------------------  --------------------------------------------------------- 
 
 c.    Price(s) and                   Price(s)    Volume(s) 
        volume(s) 
      -------------------------      ---------- 
                                      EUR1.09      40,000 
                                     ----------  ---------- 
 
       Aggregated information 
 
        - Aggregated 
        Volume                      40,000 
 
 d.     - Price                     EUR1.09 
      -------------------------  --------------------------------------------------------- 
 e.    Date of the transaction    24 March 2021 
      -------------------------  --------------------------------------------------------- 
 f.    Place of the               Turku, Finland 
        transaction 
      -------------------------  --------------------------------------------------------- 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBZLLLFXLLBBL

(END) Dow Jones Newswires

March 25, 2021 03:45 ET (07:45 GMT)